On the other hand, Bcr-Abl positively modulates, via JAK2 activation, the expression of the c-Myc oncogene, which is required for Bcr-Abl oncogenic transformation in CML. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.